Document is current
Any future updates will be listed below
-
Authors
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
Griesshammer, Martin https://orcid.org/0000-0001-8718-7004
Kiladjian, Jean-Jacques https://orcid.org/0000-0002-8121-438X
,
De Stefano, Valerio
Zaiss, Matthias
Kisro, Jens
Gückel, Eva
Großer, Susanne
Zuurman, Mike W.
Manz, Kirsi
Bryan, Kenneth
Afsharinejad, Armita
- License Information
-
More Information
Article History
Received: 28 September 2025
Revised: 1 October 2025
Accepted: 27 October 2025
First Online: 17 November 2025
Competing interests
: FHH served as an advisor for Novartis, CTI, BMS, Janssen, Abbvie, GSK, Merck, and AOP and received research funding from Novartis, Celgene/BMS and CTI. J-JK reported receiving consulting fees from AbbVie, BMS, and Novartis; payment or honoraria for lectures, presentations, or educational events from AOP, BMS/Celgene, and Novartis; participated on a DSM Board or Advisory Board for Incyte. M.G. has provided consultancy services for, and received honoraria from AOP, Novartis, BMS, AbbVie, Roche, Janssen, Gilead Sciences, AstraZeneca, Sierra, Eli Lilly and GSK.
